id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-268389-0agwvsrv	Kaminski, Monica A.	Tocilizumab Therapy of COVID-19: A Comparison of Subcutaneous and Intravenous Therapies	2020-09-28		.txt	text/plain	3409	184	47	This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on respiratory parameters and clinical outcome in patients with COVID 19. C-reactive protein levels were significantly higher in patients in the IV group that did not respond (Table 2) Lastly, laboratory markers of inflammation were analyzed before and during the seven days following tocilizumab therapy to identify trends that correlated with response involving the respiratory parameters (Table 3) . Tocilizumab has been found to be associated with improved outcomes in patients with COVID-19 related respiratory disease, particularly for patients with critical illness (i.e., requiring mechanical ventilation) (Rossotti et al., 2020 , Somers et al., 2020 . In our report, levels of C-reactive protein fell acutely in both patients that did and did not have improvement in respiratory parameters seven days following tocilizumab therapy.	./cache/cord-268389-0agwvsrv.txt	./txt/cord-268389-0agwvsrv.txt